Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6325)	5/13/2002 7:18:11 PM
From: tuck	Respond to of 52153

Peter, ESPR has more than one drug. True, APO A-1 Milano is an injectable, and so are most of the others that work the reverse lipid transport pathway. They have a lead compound in preclinical studies that is an orally active HDL elevator. And that would likely be farther away from market than PFE's drug. The indication the injectables are being tested for is atherosclerosis. As ESPR is in PII with AIM, I don't know what the dosing schedule is. You're probably right that it wouldn't be used for treatment of cholesterol, or at least not actively marketed for that. Maybe the stoic patients who can handle being stuck better than I will try it off label. Thanks. Cheers, Tuck